Warning! GuruFocus detected
2 Severe warning signs
with 8RP.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Celon Pharma SA
ISIN : PLCLNPH00015
Compare
Compare
Traded in other countries / regions
CLN.Poland8RP.Germany0RKX.UK IPO Date
2021-03-03Description
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.21 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.18 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 9.05 | |||||
| Beneish M-Score | -1.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.3 | |||||
| 3-Year EBITDA Growth Rate | -0.9 | |||||
| 3-Year EPS without NRI Growth Rate | -198.8 | |||||
| 3-Year FCF Growth Rate | -9.4 | |||||
| 3-Year Book Growth Rate | 4.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 24.32 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 43.05 | |||||
| 9-Day RSI | 48.85 | |||||
| 14-Day RSI | 51.53 | |||||
| 3-1 Month Momentum % | -11.21 | |||||
| 6-1 Month Momentum % | -14.12 | |||||
| 12-1 Month Momentum % | 52.48 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.67 | |||||
| Quick Ratio | 2.3 | |||||
| Cash Ratio | 1.43 | |||||
| Days Inventory | 157.55 | |||||
| Days Sales Outstanding | 80.98 | |||||
| Days Payable | 78.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.3 | |||||
| Dividend Payout Ratio | 0.3 | |||||
| 3-Year Dividend Growth Rate | 4 | |||||
| Forward Dividend Yield % | 0.3 | |||||
| 5-Year Yield-on-Cost % | 0.28 | |||||
| 3-Year Average Share Buyback Ratio | -4.3 | |||||
| Shareholder Yield % | -2.28 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.34 | |||||
| Operating Margin % | -27.49 | |||||
| Net Margin % | 10.3 | |||||
| FCF Margin % | -18.26 | |||||
| ROE % | 4.01 | |||||
| ROA % | 3.2 | |||||
| ROIC % | -7.25 | |||||
| 3-Year ROIIC % | 83.25 | |||||
| ROC (Joel Greenblatt) % | 8.86 | |||||
| ROCE % | 6.01 | |||||
| Years of Profitability over Past 10-Year | 5 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 87.1 | |||||
| Forward PE Ratio | 17.58 | |||||
| PE Ratio without NRI | 97.47 | |||||
| Price-to-Owner-Earnings | 74.59 | |||||
| PS Ratio | 7.93 | |||||
| PB Ratio | 2.82 | |||||
| Price-to-Tangible-Book | 2.82 | |||||
| EV-to-EBIT | 44.87 | |||||
| EV-to-EBITDA | 16.47 | |||||
| EV-to-Revenue | 7.39 | |||||
| EV-to-FCF | -41.6 | |||||
| Price-to-GF-Value | 1.04 | |||||
| Price-to-Projected-FCF | 19.77 | |||||
| Price-to-Graham-Number | 3.46 | |||||
| Price-to-Net-Current-Asset-Value | 15.72 | |||||
| Earnings Yield (Greenblatt) % | 2.23 | |||||
| FCF Yield % | -2.31 | |||||
| Forward Rate of Return (Yacktman) % | -8.25 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Celon Pharma SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 44.442 | ||
| EPS (TTM) (€) | 0.076 | ||
| Beta | 2.14 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.49 | ||
| Volatility % | 75.97 | ||
| 14-Day RSI | 51.53 | ||
| 14-Day ATR (€) | 0.215857 | ||
| 20-Day SMA (€) | 6.186 | ||
| 12-1 Month Momentum % | 52.48 | ||
| 52-Week Range (€) | 3.225 - 7.14 | ||
| Shares Outstanding (Mil) | 53.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Celon Pharma SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Celon Pharma SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Celon Pharma SA Frequently Asked Questions
What is Celon Pharma SA(FRA:8RP)'s stock price today?
The current price of FRA:8RP is €6.13. The 52 week high of FRA:8RP is €7.14 and 52 week low is €3.23.
When is next earnings date of Celon Pharma SA(FRA:8RP)?
The next earnings date of Celon Pharma SA(FRA:8RP) is .
Does Celon Pharma SA(FRA:8RP) pay dividends? If so, how much?
The Dividend Yield %  of Celon Pharma SA(FRA:8RP) is 0.3% (As of Today), Highest Dividend Payout Ratio of Celon Pharma SA(FRA:8RP) was 0.93. The lowest was 0.26. And the median was 0.3. The  Forward Dividend Yield % of Celon Pharma SA(FRA:8RP) is 0.3%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers